Clinical trials: Metabolic Evaluation
End Stage Renal Disease, Renal Impairment
A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide
The primary objective of the study is to estimate the PK parameters of ribupatide in participants with severe renal impairment or end-stage kidney disease (ESKD) after a single dose of ribupatide subcutaneous (SC) injection…
- Conditions
- End Stage Renal Disease, Renal Impairment, Obesity, Overweight
- Trial name
- NCT07793929
- Testing
- Ribupatide
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Kailera
Diabetes
Assessment of Blood Glucose Monitoring Systems - Evaluation of Oxygen Dependency
Systems for blood glucose monitoring with glucose oxidase enzyme reaction on test strips can be affected by the partial pressure of oxygen of the blood sample.
- Trial name
- IDT-1326-IU (NCT01871831)
- Testing
- 6 blood glucose monitoring systems for self-testing
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm
Diabetes Mellitus
A Study to Evaluate the Efficacy and Safety of PPB-R-203-Based Meal Versus TK9-Based Meal in 20 Patients With Diabetes
To evaluate the efficacy of PPB-R-203-Based Meal and TK9-Based Meal on blood glucose control in 20 patients with diabetes for 2 days.
- Trial name
- NCT01065402
- Testing
- PPB-R-203-Based Meal, TK9-Based Meal
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- Pharma Power Biotec Co., Ltd.
Obesity, Diabetes Mellitus, Type 2
Human Intestinal Peptides Evaluation and Research
The HIPER-1 study is a single centre cross sectional study in which a total of 240 participants (in different metabolic states and surgical models) will receive an Oral Mixed Meal Tolerance Test (OMTT).
- Trial name
- HIPER (NCT02532829)
- Testing
- blood sample analysis
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Turkish Metabolic Surgery Foundation
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)
The purpose of this study is to compare the benefits and risks of lixisenatide (AVE0010) used as 2-step initiation regimen and 1-step initiation regimen in Japan, over a period of 24 weeks of treatment, followed by an extension…
- Trial name
- GETGOAL-MONO (NCT00905255)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector
- Where
- Japan
- Volunteers
- 69 people
- Sponsor
- Sanofi
Diabetes
Natural Language Processing and Quality Assessment in Primary Care
The investigators propose to use a Natural Language Processing System (NLP) to provide an initial baseline report for primary care patients at risk for diabetes and cardiovascular complications that will include: a) evidence of…
- Trial name
- NCT01023243
- Testing
- Brochure: Care of the Feet for Those at Risk, Quality Survey: foot exam, tobacco and aspirin use
- Where
- United States
- Volunteers
- 389 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Maturity-Onset Diabetes of the Young
Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes
Maturity-onset diabetes of youth (MODY) are the most frequent monogenic diabetes with autosomic dominant inheritance (2% of diabetes).
- Trial name
- MODY2 (NCT02556840)
- Testing
- insulin therapy
- Where
- France
- Volunteers
- 46 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Essential Hypertension, Dyslipidemia
A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia
The objective of this clinical study is to evaluate the efficacy and safety by comparing the fimasartan/atorvastatin treatment group to the fimasartan/placebo treatment group and the placebo/atorvastatin treatment group…
- Trial name
- FIESTA (NCT03338426)
- Testing
- Fimasartan 120mg, Atorvastatin 40mg
- Where
- South Korea
- Volunteers
- 133 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Type 2 Diabetes
Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy Volunteers
This study is a randomized, open-label, single dose, crossover study to evaluate the pharmacokinetics and safety of CKD-383 in healthy volunteers
- Trial name
- NCT07304726
- Testing
- CKD-383 0.25/12.5/1000mg, CKD-501, D745, D150
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Obesity
A Study of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight/Obese Adult Participants and a Study of JNJ-6456511 in Otherwise Healthy Obese Adult Participants After Multiple Dose
The purpose of this study is to compare the relative bioavailability of JNJ-64565111 between subcutaneous (SC) administrations in the upper arm versus the abdomen, and between SC administrations in the thigh versus the abdomen in…
- Trial name
- NCT03586843
- Testing
- JNJ-64565111
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Heart Failure and Reduced Ejection Fraction, Obesity & Overweight
Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity
The goal of this clinical trial is to learn if tirzepatide works to improve physical function in adults with heart failure and obesity. It will also learn about the safety of tirzepatide.
- Conditions
- Heart Failure and Reduced Ejection Fraction, Obesity & Overweight, Tirzepatide
- Trial name
- DUAL-HFrEF (NCT07738276)
- Testing
- Tirzepatide
- Volunteers
- 60 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Healthy
Acute Metabolic Effects of Carbohydrate Restriction at Varying Energy Levels
This study investigates how different low-carbohydrate diets affect metabolism and hunger in overweight adults. We will measure metabolic rates and blood metabolites.
- Trial name
- NCT06387940
- Testing
- nEB Diet, followed for 36 hours, LC25 Diet, followed for 36 hours, LCEB Diet, followed for 36 hours
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Surrey
Amyotrophic Lateral Sclerosis
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis
Researchers will evaluate the safety, tolerability, and pharmacokinetics (PK) of orally administered Amisodin in healthy adult subjects through a randomized, double-blind, placebo-controlled Phase 1 study consisting of two parts…
- Trial name
- ALS (NCT07221240)
- Testing
- Amisodin
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- PRG Science & Technology Co., Ltd.
Diabetes Mellitus, Type II
Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)
The purpose of this study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.
- Trial name
- NCT00086515
- Testing
- Sitagliptin (MK0431), Metformin, Pioglitazone
- Volunteers
- 701 people
- Sponsor
- Merck Sharp & Dohme LLC
Underweight, Stunting
Evaluation Research of the Nutrition Interventions in the INHP II Areas of CARE India
This study is designed to evaluate the effectiveness of CARE India's Integrated Nutrition and Health Program (INHP II) to reduce malnutrition among children 0-23 months of age.
- Conditions
- Underweight, Stunting, Wasting, Anemia
- Trial name
- NCT00198835
- Testing
- Maternal nutrition and infant feeding advice
- Where
- India
- Volunteers
- 17,000 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Fabry Disease
A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
Fabry Disease is a rare blood disorder that some people are born with. People with Fabry disease have low levels of an enzyme called alpha-galactosidase A. This enzyme helps to cut down fat-like substances.
- Trial name
- NCT07187440
- Testing
- No intervention
- Where
- 18 sites in China
- Volunteers
- 200 people
- Sponsor
- Takeda
Diabetes
BGM and HbA1c POC Device Evaluation
This study aims to assess analytical performance of four BGMs and four HbA1c POC devices in comparison to suitable comparator or reference methods, with the view to evaluate performance in the hands of trained users, as well as…
- Trial name
- NCT06170515
- Testing
- CareSens N-Eco (i-Sens), • CareSens N-Premier (i-Sens), CodeFree (SD Biosensor), GlucoNavii GDH (SD Biosensor), Affinion (Abbott), HbA1c 501 (HemoCue), A1Care (iSens), DCA Vantage (Siemens)
- Where
- 3 sites in Cambodia, Colombia and 1 more
- Volunteers
- 910 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Quality of Life (QOL), Physical Activity
An Evaluation of "Growing Healthy Places: Mississauga"
The goal of this intervention study is to learn if community co-designed activities to improve diet and physical activity can impact the health of children ages 6-13 in Mississauga, Canada.
- Conditions
- Quality of Life (QOL), Physical Activity, Diet Quality, Obesity &Amp; Overweight
- Trial name
- NCT07191925
- Testing
- Community Co-designed Physical Activity and Diet Intervention Package
- Where
- Canada
- Volunteers
- 4,900 people, healthy volunteers welcome
- Sponsor
- Brock University
Gastroparesis, Diabetes Mellitus
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01
This study will evaluate the safety and efficacy of relamorelin compared to placebo in participants with diabetic gastroparesis. Participants will report daily severity scores of their diabetic gastroparesis symptoms.
- Trial name
- NCT03285308
- Testing
- Relamorelin
- Where
- 216 sites in United States, Australia and 12 more
- Volunteers
- 336 people
- Sponsor
- Allergan
Congenital Hyperinsulinism
RZ358 Treatment for Congenital Hyperinsulinism
The Phase 3 pivotal study is designed to evaluate the efficacy and safety of RZ358 for the treatment of congenital hyperinsulinism (HI) as add-on to standard-of-care (SOC) therapy compared to SOC alone over 24 weeks and to…
- Trial name
- sunRIZE (NCT06208215)
- Testing
- RZ358 (5-10 mg/kg) + SOC
- Where
- 18 sites in United States, Bulgaria and 11 more
- Volunteers
- 56 people
- Sponsor
- Rezolute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.